City of Hope has implemented policies and procedures to be in strict compliance with current ACCME Standards of Commercial Support requiring disclosure and resolution conflicts of interest.
Faculty Disclosure:
As part of these new commercial guidelines, we are required to disclose if Faculty , Presenters, Authors, Planners, CME Committee Members, Course Directors and / or Moderators have any real or apparent vested commercial interest(s) in both those companies whose products may be discussed/described during the course of the activity and in those companies who may be acting as commercial supporters of the activity.
City of Hope further requires that prior to the activity Faculty have disclosed their intention to discuss any off label and/or investigational (not yet approved for any purpose) use of pharmaceutics or medical devices.
Dr. Smita Bhatia has indicated that she has no relevant financial relationships to disclose
The following Planners and /or CME Committee Members have indicated that they have nothing to disclose:
Teresa Ball, Kathleen Blazer, MS, EdD, Sandra Bolton, RN, JD, Julianne Chun, Janet Crum, Ina Ervin, Jonathan Espenschied, MD, Karl Gaal, MD, Jo Hanson, RN, Fouad Kandeel, MD, Patricia Kassab, RN, MS, CTHQ, Lucille Leong, MD, Paul Lin, MD, Matthew Loscalzo, MSW, Mary Mendelsohn, RN, MSN, Robert Morgan, Jr., MD, Khanh Nguyen, MD, Anna Pawlowska, MD, I.Benjamin Paz, MD, Crystal Saavedra, BS & Jeffrey Weitzel, MD
The following Planners and /or CME Committee Members have declared they have the following relevant financial relationships to disclose:
Ravi Bhatia, MD- Consultant with
Novartis & Bristol
Myers Squibb, Martin hogan, MD- Grant/Research Support from Johnson & Johnson and Jean
Kagan, BA- Stock Shareholder with
Amgen/
Zimmer
Disclosure of Off-Label Use:
This activity may contain discussion of published and/or investigational uses of agents that are not approved/indicated by the US Food and Drug Administration (FDA). For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the official prescribing information for each product, or consult the Physicians’ Desk Reference. Participants from other r countries should consult with their respective regulatory authorities
- Dr. Smita Bhatia has indicated that she will not be discussing drugs that are off label or used for investigational purposes.
